Prosecution Insights
Last updated: November 04, 2026
Application No. 18/906,346

OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS

Non-Final OA §DOUBLEPATENT
Filed
Oct 04, 2024
Priority
Nov 25, 2013 — provisional 61/908,333 +8 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Corcept Therpeutics Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
846 granted / 1143 resolved
+14.0% vs TC avg
Strong +31% interview lift
Without
With
+31.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
68 currently pending
Career history
1197
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
49.7%
+9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1143 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION RESPONSE TO ELECTION/RESTRICTION Applicant's election with traverse of the compound Example 2C at page 55 of the disclosure and depression as the disease in the reply filed on 9/25/2026 is acknowledged. The traversal is on the ground(s) that the requirement is not the most efficient or expeditious way to proceed in terms of examiner. While the examiner not necessarily agreeing with this statement, the species requirement is hereby withdrawn. An action on the merits of claims 1-17 is contained herein. Priority This application is a continuation of and claims priority to U.S. Application 18/078,389, filed December 9, 2022, which is a Continuation Application of U.S. Application 17/146,608, filed January 12, 2021, (now U.S. Patent No. 11,560,379, issued January 24, 2024), which is a Continuation Application of U.S. Application 16/984,914, filed August 4, 2020 (now U.S. Patent No. 11,370,789 issued June 28, 2022), which is a Divisional Application of U.S. Application 16/382,474, filed April 12, 2019 (now U.S. Patent No. 10,787,449, issued September 29, 2020), which is a Divisional Application of U.S. Application 16/161,642, filed October 16, 2018 (now U.S. Patent No. 10,323,034, issued June 18, 2019), which is a Continuation of U.S. Application No. 16/036,001, filed July 16, 2018, which is a Continuation Application of U.S. Application No. 14/549,885, filed November 21, 2014 (now U.S. Patent No. 10,047,082, issued August 14, 2018), which claims priority to and the benefit of U.S. Provisional Application Nos. 61/985,035, filed April 28, 2014, and 61/908,333, filed November 25, 2013. Information Disclosure Statement The examiner has considered the references cited in the information disclosure statement filed of record. Specification Applicant is reminded of the proper content of an Abstract of the Disclosure, see MPEP 608.01(b). In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." Exemplification of a species could be illustrative of members of the class. For processes, the type reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary. It is recommended that the structure of Formula I be inserted into the abstract to accurately illustrate the claimed invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 1-17 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12, 14, and 16-17 of US Patent 10,047,082. Although the conflicting claims are not identical, they are not patentably distinct from each other because there is significant overlap between the two applications. The claims of ‘082 provide for a compound of formula I and compositions thereof. ‘082 claims differ from the instant claims only insofar as they are directed to compounds per se and not explicitly directed to a method of treating a depressive disorder. In the specification of ’082, the patentee discloses that the claimed compounds are therapeutically effective for the treatment of depression generally (column 23, lines 23-26). A patent’s “disclosure may be used…to answer the question whether claims merely define an obvious variation of what is earlier disclosed and claimed.” AbbVie v. Mathilda & Terence Kennedy Inst. of Rheumatology Trust, 112 USPQ2d 1001, 1012 (Fed. Cir. 2014)(quoting In re Bassell Poliolefine Italia S.P.A., 892 USPQ2d 1030, 1036 (Fed. Cir. 2008)). The AbbVie court explicitly noted that the Federal Circuit has “repeatedly approved examination of the disclosed utility of the invention claimed in an earlier patent to address the question of obviousness” and that “a later expiring patent is not patentably distinct from an earlier expiring patent if it merely claims a disclosed utility of the earlier claimed invention.” Id. For example, when the claims in a later-expiring patent “merely recite methods of administering” the compositions claimed in the earlier patent, they are not patentably distinct over the claims of the earlier expiring patent.” Id. (quoting Pfizer, Inc. v. Teva Pharms. USA. Inc., 86 USPQ2d 1001, 1008 (Fed. Cir. 2008)). See also Sun Pharms. Indus. Ltd. v. Eli Lilly & Co., 95 USPQ2d at 1798, 1803, in which the reference patent claimed a composition and merely remarked in passing on its “excellent oncolytic activity,” and the court held that this disclosure should have compelled a double patenting rejection in a later-filed application claiming methods of using that composition to treat cancer. Claims 1-7,9-15, and 17 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2 of US Patent 11,560,379. Although the conflicting claims are not identical, they are not patentably distinct from each other because there is significant overlap between the two applications for the reasons cited above in US Patent 10,047,082 (see col. 23, lines 39-42 of patent ‘379 in this scenario for intended use). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Oct 04, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12753196
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
3y 6m to grant Granted Oct 06, 2026
Patent 12753167
INTERMEDIATE OF BILIVERDIN, AND PREPARATION METHOD AND USE THEREOF
3y 3m to grant Granted Oct 06, 2026
Patent 12747223
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
3y 3m to grant Granted Sep 29, 2026
Patent 12741943
Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use
4y 0m to grant Granted Sep 22, 2026
Patent 12741959
Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
2y 6m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+31.2%)
2y 2m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1143 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month